Gritstone Oncology, Inc. filed on Fri, September 13 8-K

Gritstone Oncology, Inc. files 8-K in a filing on Fri, Sep 13.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On September 12, 2019, the Board of Directors (the “Board”) of Gritstone Oncology, Inc. (the “Company”) appointed Elaine Jones, Ph.D. as a Class III director with an initial term expiring at the Company’s 2021 annual meeting of stockholders. The Board also appointed Dr. Jones to serve on the Audit Committee of the Board (the “Audit Committee”). As provided in the Company’s Director Compensation Program, as amended (the “Director Compensation Program”), Dr. Jones will receive an annual cash retainer of $35,000 per year and additional annual retainers for committee service as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2019 (the “2019 Proxy Statement”). Under the Director Compensation Program, Dr. Jones was automatically granted an option to purchase 15,942 shares of the Company’s common stock (the “Initial Option”), pursuant to the Company’s 2018 Incentive Award Plan (the “2018 Plan”). The Initial Option will vest in substantially equal monthly installments for three years from the date of grant, subject to continued service through each applicable vesting date. In addition, following each annual meeting of the Company’s stockholders, Dr. Jones will automatically be granted an option to purchase 8,570 shares of the Company’s common stock (the “Annual Option”), pursuant to the 2018 Plan. Each Annual Option will vest in full on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder’s meeting, subject to continued service through such date. The Company also entered into the Company’s standard indemnification agreement with Dr. Jones. Please see the descriptions of the Company’s standard indemnification agreement and the 2018 Plan contained in the 2019 Proxy Statement for additional information. Dr. Jones is not a party to any transaction of the type listed in Item 404(a) of Regulation S-K and does not have any family relationships with any of the Company’s directors or executive officers. Director Resignation On September 12, 2019, Peter Svennilson notified the Board of his decision to resign from the Board, effective immediately, for personal reasons, and not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Jones filled the vacancies on the Board and Audit Committee left by Mr. Svennilson’s resignation.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 12, 2019, the Board of Directors (the “Board”) of Gritstone Oncology, Inc. (the “Company”) appointed Elaine Jones, Ph.D. as a Class III director with an initial term expiring at the Company’s 2021 annual meeting of stockholders. The Board also appointed Dr. Jones to serve on the Audit Committee of the Board (the “Audit Committee”).

As provided in the Company’s Director Compensation Program, as amended (the “Director Compensation Program”), Dr. Jones will receive an annual cash retainer of $35,000 per year and additional annual retainers for committee service as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2019 (the “2019 Proxy Statement”). Under the Director Compensation Program, Dr. Jones was automatically granted an option to purchase 15,942 shares of the Company’s common stock (the “Initial Option”), pursuant to the Company’s 2018 Incentive Award Plan (the “2018 Plan”). The Initial Option will vest in substantially equal monthly installments for three years from the date of grant, subject to continued service through each applicable vesting date. In addition, following each annual meeting of the Company’s stockholders, Dr. Jones will automatically be granted an option to purchase 8,570 shares of the Company’s common stock (the “Annual Option”), pursuant to the 2018 Plan. Each Annual Option will vest in full on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder’s meeting, subject to continued service through such date. The Company also entered into the Company’s standard indemnification agreement with Dr. Jones. Please see the descriptions of the Company’s standard indemnification agreement and the 2018 Plan contained in the 2019 Proxy Statement for additional information.

Dr. Jones is not a party to any transaction of the type listed in Item 404(a) of Regulation S-K and does not have any family relationships with any of the Company’s directors or executive officers.

On September 12, 2019, Peter Svennilson notified the Board of his decision to resign from the Board, effective immediately, for personal reasons, and not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Jones filled the vacancies on the Board and Audit Committee left by Mr. Svennilson’s resignation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.